Skip to main content
Skip to main content

Equities

Equity selloff could prove sharp but limited if Fed tightening headwinds fade, given solid AI fundamentals and a resilient economy. Markets entered liquidation mode on Friday, with risk assets falling alongside lower global yields and a softer dollar. The S&P…
A disinflationary backdrop next year and falling yields create a highly favorable setup for packaged foods stocks within consumer staples. These stocks are often viewed as bond proxies, as they are defensive in nature and their high dividend yields offer an…
September TIC data showed strong foreign inflows into US securities, but their bias toward risk assets leaves the dollar vulnerable to corrections. Total net purchases of US assets rose to $261bn from $203bn in August, led by private inflows, with a modest…
A pullback in neocloud buildouts would strengthen the hyperscalers’ hand, according to our strategists at this month’s BCA Views Meeting, though they split on whether the AI cycle is nearing a top. Since July, the hyperscalers have delivered a total return of…

Expect Democrats to heed voters and pursue policies to reduce prices. The ousting of Huang is a blow to the neoclouds but a gift to frontier labs and hyperscalers. Downgrade Health Care and upgrade Consumer Discretionary. Upgrade Europe. Continue to favor the hyperscalers within the AI universe.

Rising implied correlation could expose the market to a sharp VIX repricing. Global equities resumed their slide on Monday as the semiconductor-led selloff spread to Asian and US markets. The Nasdaq 100 fell more than 2.5%, as markets weighed Nvidia’s…

Health Care’s second-half 2026 rally has largely been a defensive rotation, not the start of a new bull market. Health Care leadership is more typical when the economy is slowing/contracting and is hard to sustain in a rising market. With the cycle still firm and our expectation that the market rallies into year end, we are neutral on the sector, though we recognize its hedging value. Within Health Care, we are underweight Providers & Services, overweight Equipment & Supplies, and market weight Pharmaceuticals, Biotech & Life Sciences (“Pharma”).

Our clients have a positive outlook on European stocks in the latest poll. Of our clients, 44% chose “Buy Europe,” 29% chose “Europe is doomed,” and 26% sat in the middle. Social media respondents were more cautious. On LinkedIn, 49% were in the middle, 31%…
A sector-neutral view confirms that Europe’s valuation discount to the US persists, supporting the case for European equities. The usual objection to the region’s low multiples is its sector mix. Europe is overweight low-multiple financials and energy, and…

Europe was shunned while AI could do no wrong. That trade is looking tired. Falling energy prices and cracks in the AI boom favor rotating out of US equities and into cheaper European stocks. Favor defensives: Europe can win the relative race even if both markets fall.